Physician profile
Eric M Byman
NPI 1962457275
$2,531.80
in general payments reported to CMS, 2019-2025
17 companies · $64.80 in 2025
The $64.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $151 · 2021: $390 · 2022: $217 · 2023: $608 · 2024: $488 · 2025: $64.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $934 · Food and Beverage: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $933.50 |
| Food and Beverage | $226.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $994.66 | 2023-2025 | Ubrelvy |
| Allergan, INC. | $491.08 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $206.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $200.42 | 2019-2020 | |
| Amgen INC. | $155.48 | 2019 | |
| Pfizer INC. | $111.35 | 2019-2022 | |
| Horizon Therapeutics Plc | $104.72 | 2023 | Krystexxa |
| Galderma Laboratories, L.P. | $70.85 | 2019-2021 | |
| Dexcom, INC. | $48.87 | 2022-2023 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $38.19 | 2019 | |
| Lilly USA, LLC | $26.12 | 2019 | |
| Hikma Pharmaceuticals USA | $15.15 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.45 | 2019 | |
| Novo Nordisk INC | $14.20 | 2019 | |
| Shire North American Group INC | $13.57 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.04 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Byman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.